Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | RHOA | P61586 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE8B | O95263 | 4/20 | 0.47 |
| ▸ | PDE8A | O60658 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17729065 | 0.93 | RHOA (0.60) | RAB9ARHOASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL17773239 | 0.78 | CNR1 (0.53) | RAB9ARHOAPOLBALDH1A1TP53BP1 | |
| SCHEMBL17773257 | 0.78 | RHOA (0.55) | RAB9ARHOAKDM4ESMN1; SMN2TP53BP1 | |
| SCHEMBL17773250 | 0.76 | FLT3 (0.55) | RAB9ARHOAKDM4EGAASMN1; SMN2 | |
| SCHEMBL25668693 | 0.74 | RAB9A (0.72) | RAB9ARHOAKDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL17773205 | 0.74 | RAB9A (0.54) | RAB9ARHOAKDM4ESMN1; SMN2POLB | |
| SCHEMBL17773212 | 0.73 | RHOA (0.64) | RAB9ARHOA | |
| SCHEMBL17773190 | 0.72 | RHOA (0.67) | RAB9ARHOAPOLBALDH1A1 | |
| SCHEMBL17773268 | 0.72 | RHOA (0.59) | RAB9ARHOASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL17773267 | 0.72 | RHOA (0.60) | RAB9ARHOASMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | SREBF1, SREBF2, BPTF | RAB9A 2184/4885RHOA 229/4885KDM4E 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.